Successful treatment with liposomal amphotericin B in two patients with persisting fungemia.

Abstract

Two granulocytopenic patients in whom fungemia persisted despite therapy with deoxycholate amphotericin B were subsequently successfully treated by daily intravenous administration of amphotericin B entrapped in sonicated liposomes made of egg yolk lecithin, cholesterol and stearylamine in a molar ratio of 4:3:1. High serum concentrations of amphotericin B could be maintained in both patients during therapy with liposomal amphotericin B and were associated with high in vitro antifungal activity. Liposomal amphotericin B was tolerated much better than the deoxycholate preparation. These findings suggest that the liposomal amphotericin B preparation is superior in the treatment of fungemia in granulocytopenic patients, and that randomized trials are warranted.

• Authors: J P Sculier, D Bron, A Coune, F Meunier
• Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 8 Issue 10 Pg. 903-7 (Oct 1989) ISSN: 0934-9723 [Print] Germany
• PMID: 2512139 (Publication Type: Case Reports, Journal Article)

Chemical References

• Drug Carriers
• Liposomes
• Amphotericin B

Topics

• Agranulocytosis (complications)
• Amphotericin B (administration & dosage)
• Candidiasis (blood, complications, drug therapy)
• Drug Carriers
• Female
• Humans
• Liposomes
• Male
• Middle Aged
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (complications)